Jefferson University Hospitals

Physician Profile

William Kelly, DO

Jefferson University Physician

Academic Title: Professor

Specialties
Medical Oncology
Medical Oncology - Bladder Cancer
Medical Oncology - Kidney Cancer
Medical Oncology - Prostate Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-7697

Medical Services

Board Certifications

  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Education

  • Philadelphia College of Osteopathic Medicine, Medical School

Internship

  • St Joseph's Hospital

Residency

  • Albert Einstein Medical Center, Philadelphia, PA

Fellowship

  • Weill Cornell Medical Center - New York Presbyterian Hospital
  • Memorial Hospital for Cancer & Allied Disease

Recent Publications

Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials

Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies

Indoleamine 2, 3-dioxygenase (IDO): Biology and target in cancer immunotherapies

A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone for patientswithmetastatic castration-resistant prostate cancer progressing on abiraterone

Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report

Pharmacogenetic discovery in CALGB (alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy

Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma

Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer

Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3

The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3

A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer

Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer

Practical guide to the use of enzalutamide

Effect of docetaxel on safety and efficacy of radium-223

Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer